A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice
- Autoimmune Disorder
- Rheumatoid Arthritis
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice. Participants will be observed for up to 52 weeks after starting treatment with tocilizumab. All visits and assessments will be performed as per routine clinical practice, with no study-specific visits or interventions.
A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice
- Diagnosis of moderate to severe RA, defined as DAS28 greater than or equal to 3.7
- Naive to tocilizumab, or received tocilizumab within 8 weeks prior to enrollment
- Physician has made decision to commence IV or SC tocilizumab in accordance with label and reimbursement criteria
- Treated with glucocorticoids for RA when starting tocilizumab treatment
- Treatment with any investigational agent within 4 weeks or 5 half-lives before tocilizumab
- Continuous or regular treatment with oral corticosteroids for any indication other than RA
For the latest version of this information please go to www.forpatients.roche.com